[{"address1": "42127 Pleasant Forest Court", "city": "Ashburn", "state": "VA", "zip": "20148-7349", "country": "United States", "phone": "703 980 4182", "website": "https://quoinpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael  Myers Ph.D.", "age": 61, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 661800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Denise  Carter", "age": 54, "title": "Co-Founder, COO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 537800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gordon Bruce Dunn J.D.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 394200, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.597, "open": 0.6015, "dayLow": 0.58, "dayHigh": 0.6015, "regularMarketPreviousClose": 0.597, "regularMarketOpen": 0.6015, "regularMarketDayLow": 0.58, "regularMarketDayHigh": 0.6015, "beta": 2.041, "forwardPE": -0.4172662, "volume": 36239, "regularMarketVolume": 36239, "averageVolume": 56015, "averageVolume10days": 61010, "averageDailyVolume10Day": 61010, "marketCap": 2308382, "fiftyTwoWeekLow": 0.58, "fiftyTwoWeekHigh": 12.0, "fiftyDayAverage": 0.70614, "twoHundredDayAverage": 2.79007, "currency": "USD", "enterpriseValue": -9007856, "floatShares": 3960588, "sharesOutstanding": 3979970, "sharesShort": 5169, "sharesShortPriorMonth": 2755, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0013, "heldPercentInsiders": 0.00487, "heldPercentInstitutions": 0.06451, "shortRatio": 0.15, "shortPercentOfFloat": 0.0013, "bookValue": 2.404, "priceToBook": 0.24126455, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8410784, "trailingEps": -6.66, "forwardEps": -1.39, "enterpriseToEbitda": 1.006, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNRX", "underlyingSymbol": "QNRX", "shortName": "Quoin Pharmaceuticals, Ltd.", "longName": "Quoin Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1470058200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "32cb2815-c927-3d74-8136-d444e5765139", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.58, "targetHighPrice": 10.0, "targetLowPrice": 2.45, "targetMeanPrice": 5.48, "targetMedianPrice": 4.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 14689972, "totalCashPerShare": 3.691, "ebitda": -8958543, "totalDebt": 3373733, "quickRatio": 3.478, "currentRatio": 3.614, "debtToEquity": 36.97, "returnOnAssets": -0.32759997, "returnOnEquity": -0.83940005, "freeCashflow": -4485781, "operatingCashflow": -7552266, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]